Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

The Drugs industry as a whole closed the day down 0.2% versus the S&P 500, which was down 0.2%. Laggards within the Drugs industry included Tianyin Pharmaceutical ( TPI), down 6.1%, XTL Biopharmaceuticals ( XTLB), down 5.2%, China Pharma ( CPHI), down 11.5%, Acasti Pharma ( ACST), down 2.6% and Kamada ( KMDA), down 3.7%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Kamada ( KMDA) is one of the companies that pushed the Drugs industry lower today. Kamada was down $0.14 (3.7%) to $3.65 on heavy volume. Throughout the day, 77,824 shares of Kamada exchanged hands as compared to its average daily volume of 21,900 shares. The stock ranged in price between $3.58-$3.72 after having opened the day at $3.61 as compared to the previous trading day's close of $3.79.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. Kamada has a market cap of $139.1 million and is part of the health care sector. Shares are down 0.3% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Kamada a buy, no analysts rate it a sell, and 1 rates it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Kamada as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on KMDA go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 69.6% when compared to the same quarter one year ago, falling from -$3.12 million to -$5.29 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, KAMADA LTD's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for KAMADA LTD is currently extremely low, coming in at 13.02%. It has decreased significantly from the same period last year. Along with this, the net profit margin of -59.28% is significantly below that of the industry average.
  • Net operating cash flow has decreased to -$2.01 million or 29.96% when compared to the same quarter last year. Despite a decrease in cash flow of 29.96%, KAMADA LTD is still significantly exceeding the industry average of -81.18%.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 48.37%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 66.66% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: Kamada Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, China Pharma ( CPHI) was down $0.03 (11.5%) to $0.23 on light volume. Throughout the day, 32,475 shares of China Pharma exchanged hands as compared to its average daily volume of 85,000 shares. The stock ranged in price between $0.22-$0.25 after having opened the day at $0.25 as compared to the previous trading day's close of $0.26.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. China Pharma has a market cap of $11.3 million and is part of the health care sector. Shares are down 13.4% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates China Pharma as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on CPHI go as follows:

  • CHINA PHARMA HOLDINGS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, CHINA PHARMA HOLDINGS INC reported poor results of -$0.60 versus -$0.45 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 233.6% when compared to the same quarter one year ago, falling from -$2.39 million to -$7.97 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, CHINA PHARMA HOLDINGS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$0.00 million or 100.08% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 34.38%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 260.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: China Pharma Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

XTL Biopharmaceuticals ( XTLB) was another company that pushed the Drugs industry lower today. XTL Biopharmaceuticals was down $0.10 (5.2%) to $1.87 on light volume. Throughout the day, 500 shares of XTL Biopharmaceuticals exchanged hands as compared to its average daily volume of 6,300 shares. The stock ranged in price between $1.87-$1.87 after having opened the day at $1.87 as compared to the previous trading day's close of $1.97.

XTL Biopharmaceuticals has a market cap of $25.8 million and is part of the health care sector. Shares are down 0.3% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates XTL Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.